TCGA-E2-A153-01A-12R-A12D-07
Mesenchymal profile
This tumor’s EMT hallmark activation ranks 1 of 50 hallmark pathways (GSVA = 0.700). It is a mesenchymal-high tumor — a candidate for EMT-reversal targeting.
Predicted reversal drugs for this tumor
| Drug | Reversal | Adj. score | On-target | Calibrated |
|---|---|---|---|---|
| Palbociclib | -0.088 | -0.117 | 0% | speculative |
| Encorafenib | -0.115 | -0.158 | -51% | — |
| Gedatolisib | -0.133 | -0.174 | 0% | — |
| Asciminib | -0.141 | -0.183 | 0% | — |
| Duvelisib | -0.135 | -0.183 | 0% | — |
| Tepotinib | -0.135 | -0.184 | 0% | — |
| Abemaciclib | -0.145 | -0.186 | 0% | — |
| Leniolisib | -0.147 | -0.191 | 0% | — |
| Defactinib | -0.157 | -0.192 | 0% | — |
| Deucravacitinib | -0.152 | -0.207 | 45% | — |
| Futibatinib | -0.153 | -0.208 | 53% | — |
| Capivasertib | -0.159 | -0.210 | 0% | — |
| Selumetinib | -0.159 | -0.210 | 0% | speculative |
| Darovasertib | -0.156 | -0.213 | 0% | — |
| Cobimetinib | -0.163 | -0.216 | 0% | — |
| Dabrafenib | -0.168 | -0.221 | -30% | speculative |
| Acalabrutinib | -0.165 | -0.221 | 46% | — |
| Tenalisib | -0.164 | -0.221 | 0% | — |
| Ceritinib | -0.169 | -0.221 | -116% | — |
| Abrocitinib | -0.172 | -0.222 | 57% | — |
Measured anti-mesenchymal leaders (Table S9)
Catalog-level reference: the drugs with the strongest S9 expression-weighted coverage of the mesenchymal kinase program, independent of this tumor.
Gilteritinib (49%)Pacritinib (49%)Ponatinib (47%)Midostaurin (45%)Sunitinib (45%)Bosutinib (44%)Nintedanib (43%)Brigatinib (40%)Repotrectinib (38%)Crizotinib (36%)